104208 Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 

positive COVID–19 test result may be 

submitted by 3pm the business day 

prior to the hearing. Further information 

about participation in the hearing will 

be posted on the Commission’s website 

at https://www.usitc.gov/calendarpad/ 

calendar.html. 

A nonparty who has testimony that 

may aid the Commission’s deliberations 

may request permission to present a 

short statement at the hearing. All 

parties and nonparties desiring to 

appear at the hearing and make oral 

presentations should attend a 

prehearing conference, if deemed 

necessary, to be held at 9:30 a.m. on 

Tuesday, April 15, 2025. Parties shall 

file and serve written testimony and 

presentation slides in connection with 

their presentation at the hearing by no 

later than noon on April 14, 2025. Oral 

testimony and written materials to be 

submitted at the public hearing are 

governed by sections 201.6(b)(2), 

201.13(f), and 207.24 of the 

Commission’s rules. Parties must submit 

any request to present a portion of their 

hearing testimony in camera no later 

than 7 business days prior to the date of 

the hearing. 

Written submissions—Each party who 

is an interested party shall submit a 

prehearing brief to the Commission. 

Prehearing briefs must conform with the 

provisions of § 207.23 of the 

Commission’s rules; the deadline for 

filing is April 10, 2025. Parties shall also 

file written testimony in connection 

with their presentation at the hearing, 

and posthearing briefs, which must 

conform with the provisions of § 207.25 

of the Commission’s rules. The deadline 

for filing posthearing briefs is April 24, 

2025. In addition, any person who has 

not entered an appearance as a party to 

the investigations may submit a written 

statement of information pertinent to 

the subject of the investigations, 

including statements of support or 

opposition to the petition, on or before 

April 24, 2025. On May 12, 2025, the 

Commission will make available to 

parties all information on which they 

have not had an opportunity to 

comment. Parties may submit final 

comments on this information on or 

before May 14, 2025, but such final 

comments must not contain new factual 

information and must otherwise comply 

with § 207.30 of the Commission’s rules. 

All written submissions must conform 

with the provisions of § 201.8 of the 

Commission’s rules; any submissions 

that contain BPI must also conform with 

the requirements of §§ 201.6, 207.3, and 

207.7 of the Commission’s rules. The 

Commission’s Handbook on Filing 

Procedures, available on the 

Commission’s website at https://

www.usitc.gov/documents/handbook_

on_filing_procedures.pdf, elaborates 

upon the Commission’s procedures with 

respect to filings. 

Additional written submissions to the 

Commission, including requests 

pursuant to § 201.12 of the 

Commission’s rules, shall not be 

accepted unless good cause is shown for 

accepting such submissions, or unless 

the submission is pursuant to a specific 

request by a Commissioner or 

Commission staff. 

In accordance with §§ 201.16(c) and 

207.3 of the Commission’s rules, each 

document filed by a party to the 

investigations must be served on all 

other parties to the investigations (as 

identified by either the public or BPI 

service list), and a certificate of service 

must be timely filed. The Secretary will 

not accept a document for filing without 

a certificate of service. 

Authority: These investigations are 

being conducted under authority of title 

VII of the Tariff Act of 1930; this notice 

is published pursuant to § 207.21 of the 

Commission’s rules. 

By order of the Commission. 

Issued: December 16, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–30379 Filed 12–19–24; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—1EdTech Consortium, Inc. 

Notice is hereby given that, on July 

16, 2024, pursuant to section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), 1EdTech 

Consortium, Inc. (‘‘1EdTech 

Consortium’’) has filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Alabama Institute for 

Deaf and Blind, East Talladega, AL; 

Education Assessment System, 

Arlington, VA; University of Georgia, 

Athens, GA; School Harbor, Phoenix, 

AZ; Ivy Tech Community College, 

Indianapolis, IN; MyEducator LLC, 

Orem, UT; Mountain Brook Schools, 

Mountain Brook, AL; Uinta County 

School District #1, Evanston, WY; St. 

Charles CUSD 303, St. Charles, IL; 

Swedish National Agency for Education 

(Statens skolverk), Stockholm, 

SWEDEN; Massachusetts Institute of 

Technology, Cambridge, MA; and 

Vestavia Hills City Schools, Vestavia 

Hills, AL, have been added as parties to 

this venture. 

Also, Washington State Community 

and Technical Colleges System, 

Olympia, WA; Pearl, Richmond, VA; 

New Hanover County Schools, 

Wilmington, NC; and Edge Factor Inc., 

Ontario, CANADA, have withdrawn as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and 1EdTech 

Consortium intends to file additional 

written notifications disclosing all 

changes in membership. 

On April 7, 2000, 1EdTech 

Consortium filed its original notification 

pursuant to section 6(a) of the Act. The 

Department of Justice published a notice 

in the Federal Register pursuant to 

section 6(b) of the Act on September 13, 

2000 (65 FR 55283). 

The last notification was filed with 

the Department on April 29, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on June 21, 2024 (89 FR 52089). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30406 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Rapid Response 

Partnership Vehicle 

Notice is hereby given that, on 

October 3, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), Rapid Response 

Partnership Vehicle (‘‘RRPV’’) has filed 

written notifications simultaneously 

with the Attorney General and the 

Federal Trade Commission disclosing 

changes in its membership. The 

notifications were filed for the purpose 

of extending the Act’s provisions 

limiting the recovery of antitrust 

plaintiffs to actual damages under 

specified circumstances. 

Specifically, Biointelect Pty, Ltd., 

Sydney, AUSTRALIA; SPI Pharma, Inc., 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 245 / Friday, December 20, 2024 / Notices 104209 

Wilmington, DE; Serimmune, Goleta, 

CA; UNITED KINGDOM HEALTH 

SECURITY AGENCY (UKHSA), 

Salisbury, UNITED KINGDOM; 

University of Connecticut, Farmington, 

CT; VGXI, Inc., Conroe, TX; ABSS 

Solutions, Inc., Upper Marlboro, MD; 

BiosYnth SRL, Milan, ITALY; Idevax, 

Wijnegem, BELGIUM; IntegerBio, Inc., 

Gaithersburg, MD; Phoreus 

Biotechnology, Inc., Olathe, KS; 

PrecNA, LLC, North Potomac, MD; 

Sepragen Corp., Union City, CA; Trellis 

Bioscience, Inc., Redwood City, CA; AB 

Validation, Inc., Quebec, CANADA; 

AuraVax Therapeutics, Inc., Houston, 

TX; CuriRx, Inc., Wilmington, MA; IMA 

Evaluations, LLC, dba IMA Clinical 

Research, Tarrytown, NY; MustardSeed 

PMO, West Chester, PA; Symbiosis.io, 

LLC, Smyrna, GA; Tornado 

Therapeutics, Boston, MA; Amneal 

Pharmaceuticals of New York, LLC, 

Brookhaven, NY; Blue Spark 

Technologies, Inc., Westlake, OH; 

Inhalon Biopharma, Inc., Morrisville, 

NC; Intelligene, Inc., Taipei, TAIWAN; 

Rocket Science Health US Corp., Seattle, 

WA; Rutgers, The State University of 

New Jersey, Piscataway, NJ; The 

Administrators of the Tulane 

Educational Fund, New Orleans, LA; 

Verisim Life, Inc., San Francisco, CA; 

Arcturus Therapeutics Holdings, Inc., 

San Diego, CA; Blu Zone Bioscience & 

Supply Chain Solutions, LLC, Frederick, 

MD; Elligo Health Research, Inc., 

Austin, TX; Guide Biomedical 

Solutions, LLC, Media, PA; Integral 

Molecular, Philadelphia, PA; Komo 

Biosciences, Inc., Newton, MA; P95, BV, 

Leuven, BELGIUM; Southwest Research 

Institute, San Antonio, TX; Statistics & 

Data Corp., Tempe, AZ; Stoic Bio, Inc., 

San Diego, CA; Valaria Technical 

Consultants, LLC, Westminster, MD; 

Vaxine Pty, Ltd., Marion, AUSTRALIA; 

Zeteo Biomedical, LLC, Austin, TX; 

Concept to Market, LLC, Monrovia, MD; 

DSBio Consulting, LLC, Annapolis, MD; 

Deimos Biosciences, San Francisco, CA; 

GMED North America, Inc., Rockville, 

MD; InvisiShield Technologies, Ltd., 

Emeryville, CA; MigVax, Ltd., Kiryat 

Shmona, ISRAEL; Polaris Alpha 

Advanced Systems, Inc., 

Fredericksburg, VA; Pop Test Oncology, 

LLC, Cliffside Park, NJ; Sapphiros, 

Boston, MA; Articulate Labs, Inc., 

Dallas, TX; Empatica, Inc., Cambridge, 

MA; LifeMine Therapeutics, Inc., 

Cambridge, MA; Luminous 

Therapeutics Corp., Columbia, MD; 

Nabla Bio, Inc., Cambridge, MA; 

Qoolabs, Inc., Carlsbad, CA; Rapid 

Novor, Inc., Kitchener, CANADA; 

Scorpius BioManufacturing, San 

Antonio, TX; Sunflower Therapeutics 

PBC, Medford, MA; GreenRoads 

Diagnostics, Inc., San Diego, CA; Logical 

Images, dba ‘‘VisualDx’’, Rochester, NY; 

Mirai Biosciences, Cambridge, MA; The 

Scripps Research Institute, La Jolla, CA; 

AmplifyBio, LLC, West Jefferson, OH; 

Andelyn Biosciences, Inc., Columbus, 

OH; Binary Pharmaceuticals, LLC, Hot 

Springs, AR; BioCina PTY, Ltd., West 

Torrens, AUSTRALIA; Cypress 

Biologics, LLC, Portland, OR; Fermeate, 

Inc., San Francisco, CA; HMH Hospitals 

Corp, dba CDI, Nutley, NJ; Meso Scale 

Diagnostics, LLC, Rockville, MD; 

Systems & Technology Research, LLC, 

Woburn, MA; Telesis Bio, San Diego, 

CA; Thermo Fisher, South San 

Francisco, CA; University of 

Massachusetts Lowell, Lowell, MA; 

ViQi, Inc., Santa Barbara, CA; 

DemeTech Corp., Miami, FL; INFEX 

Therapeutics, Alderley Edge, UNITED 

KINGDOM; Mercury Bio, Inc., Santa Fe, 

NM; Phageolytix, Inc., Jacksonville, FL; 

Phenom Pharmaceuticals, LLC, Miami 

Beach, FL; RIBOPRO BV, Oss, 

NETHERLANDS; RNhale GmbH, 

Munich, GERMANY; The University of 

Chicago Medicine, Chicago, IL; Bioblue 

CMC/Manufacturing Consulting, LLC, 

San Diego, CA; Oligo Foundry, Inc., San 

Diego, CA; PNUVAX, Inc., Wilmington, 

DE; Prosoft Software, Inc., dba Prosoft 

Clinical, Chesterbrook, PA; Simon 

Williams Pharma Consulting (SWPC), 

LLC, Gibbsboro, NJ; Dillico, Meylan, 

FRANCE; INFINIFLUIDICS, 

Philadelphia, PA; Primrose Bio, Inc., 

San Diego, CA; SIMETRI, Inc., Winter 

Park, FL; The Trustees of the University 

of Pennsylvania, Philadelphia, PA; and 

WCG, Princeton, NJ, have been added as 

parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and RRPV intends 

to file additional written notifications 

disclosing all changes in membership. 

On January 5, 2024, RRPV filed its 

original notification pursuant to section 

6(a) of the Act. The Department of 

Justice published a notice in the Federal 

Register pursuant to section 6(b) of the 

Act on April 16, 2024 (89 FR 26928). 

The last notification was filed with 

the Department on July 11, 2024. The 

Department of Justice published a notice 

in the Federal Register pursuant to 

section 6(b) of the Act on October 11, 

2024 (89 FR 82631). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30403 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—UHD Alliance 

Notice is hereby given that, on 

October 8, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), UHD Alliance, 

Inc. (‘‘UHD Alliance’’) filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, TTE Corporation, 

Shenzhen, PEOPLE’S REPUBLIC OF 

CHINA has been added as a party to this 

venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and UHD Alliance 

intends to file additional written 

notifications disclosing all changes in 

membership. 

On June 17, 2015, UHD Alliance filed 

its original notification pursuant to 

section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to section 

6(b) of the Act on July 17, 2015 (80 FR 

42537). 

The last notification was filed with 

the Department on July 8, 2024. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on September 26, 2024 (89 FR 

78904). 

Suzanne Morris, 

Deputy Director Civil Enforcement 

Operations, Antitrust Division. 

[FR Doc. 2024–30412 Filed 12–19–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Subcutaneous Drug 

Development & Delivery Consortium, 

Inc. 

Notice is hereby given that, on 

October 4, 2024, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), Subcutaneous 

Drug Development & Delivery 


ddrumheller on DSK120RN23PROD with NOTICES1